中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

36 records (took 0.014 seconds)

    POLYMORPHISMS IN THE HUMAN GENE FOR CYTOCHROME P450 POLYPEPTIDE 2C8 AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS
    11.
    发明申请
    POLYMORPHISMS IN THE HUMAN GENE FOR CYTOCHROME P450 POLYPEPTIDE 2C8 AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS 审中-公开
    人类基因组P450多肽2C8的多态性及其在诊断和治疗应用中的应用

    公开(公告)号：WO2002099099A2

    公开(公告)日：2002-12-12

    申请号：PCT/EP2002/006000

    申请日：2002-05-31

    Applicant: EPIDAUROS BIOTECHNOLOGIE AG ,  PENGER, Anja ,  SPRENGER, Reimund ,  BRINKMANN, Ulrich

    Inventor： PENGER, Anja ,  SPRENGER, Reimund ,  BRINKMANN, Ulrich

    IPC: C12N15/00

    CPC classification number: C12N9/0077 ,  A01K2217/05 ,  C12Q1/6883 ,  C12Q2600/156

    Abstract: The present invention relates to a polymorphic CYP2C8-polynucleotide. Moreover, the invention relates to genes or vectors comprising the polynucleotides of the invention and to a host cell genetically engineered with the polynucleotide or gene of the invention. Further, the invention relates to methods for producing molecular variant polypeptides or fragments thereof, methods for producing cells capable of expressing a molecular variant polypeptide and to a polypeptide or fragment thereof encoded by the polynucleotide or the gene of the invention or which is obtainable by the method or from the cells produced by the method of the invention. Furthermore, the invention relates to an antibody which binds specifically the polypeptide of the invention. Moreover, the invention relates to a transgenic non-human animal. The invention also relates to a solid support comprising one or a plurality of the above mentioned polynucleotides, genes, vectors, polypeptides, antibodies or host cells. Furthermore, methods of identifying a polymorphism, identifying and obtaining a prodrug or drug or an inhibitor are also encompassed by the present invention. In addition, the invention relates to methods for producing of a pharmaceutical composition and to methods of diagnosing a disease. Further, the invention relates to a method of detection of the polynucleotide of the invention. Furthermore, comprised by the present invention are a diagnostic and a pharmaceutical composition. Even more, the invention relates to uses of the polynucleotides, genes, vectors, polypeptides or antibodies of the invention. Finally, the invention relates to a diagnostic kit.

    Abstract translation: 本发明涉及多态CYP2C8-多核苷酸。 此外，本发明涉及包含本发明的多核苷酸的基因或载体，并涉及用本发明的多核苷酸或基因进行遗传工程改造的宿主细胞。 此外，本发明涉及用于产生分子变体多肽或其片段的方法，用于产生能够表达分子变体多肽的细胞的方法，以及由本发明的多核苷酸或基因编码的多肽或其片段，或可由 方法或由本发明方法生产的细胞。 此外，本发明涉及特异性结合本发明多肽的抗体。 此外，本发明涉及转基因非人动物。 本发明还涉及包含一种或多种上述多核苷酸，基因，载体，多肽，抗体或宿主细胞的固体支持物。 此外，鉴定多态性，鉴定和获得前药或药物或抑制剂的方法也包括在本发明中。 此外，本发明涉及制备药物组合物的方法和诊断疾病的方法。 此外，本发明涉及本发明的多核苷酸的检测方法。 此外，本发明包括诊断和药物组合物。 更进一步地，本发明涉及本发明的多核苷酸，基因，载体，多肽或抗体的用途。 最后，本发明涉及诊断试剂盒。

    POLYMORPHISMS IN THE HUMAN CYP3A4 AND CYP3A7 GENES AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS
    12.
    发明申请
    POLYMORPHISMS IN THE HUMAN CYP3A4 AND CYP3A7 GENES AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS 审中-公开
    人CYP3A4和CYP3A7基因多态性及其在诊断和治疗应用中的应用

    公开(公告)号：WO0120025A3

    公开(公告)日：2001-10-11

    申请号：PCT/EP0008570

    申请日：2000-09-01

    Applicant: EPIDAUROS BIOTECHNOLOGIE AG ,  WOJNOWSKI LESZEK ,  EISELT REGINA

    Inventor： WOJNOWSKI LESZEK ,  EISELT REGINA

    IPC: A01K67/027 ,  A61K31/7088 ,  A61K35/56 ,  A61K35/76 ,  A61K38/00 ,  A61K38/17 ,  A61K39/395 ,  A61K45/00 ,  A61K48/00 ,  A61P35/00 ,  A61P43/00 ,  C07K14/705 ,  C07K16/18 ,  C07K16/28 ,  C07K16/40 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N9/02 ,  C12N15/09 ,  C12N15/53 ,  C12P19/34 ,  C12P21/02 ,  C12Q1/68 ,  G01N33/15 ,  G01N33/50 ,  G01N33/53 ,  G01N33/566 ,  G01N33/574

    CPC classification number: C07K14/70567 ,  A01K2217/05 ,  C12N9/0077 ,  C12Q1/6883 ,  C12Q2600/156 ,  C12Q2600/158

    Abstract: Described are general means and methods of diagnosing and treating the phenotypic spectrum as well as the overlapping clinical characteristics with several forms of inherited abnormal expression and/or function of the CYP3A4 and CYP3A7 genes. In particular, polynucleotides of molecular variant CYP3A4 and CYP3A7 genes which, for example, are associated with insufficient metabolization and/or sensitivety of drugs, and vectors comprising such polynucleotides are provided. Furthermore, host cells comprising such polynucleotides or vectors and their use for the production of variant CYP3A4 and CYP3A7 proteins are described. In addition, variant CYP3A4 and CYP3A7 proteins and antibodies specifically recognizing such proteins as well as transgenic non-human animals comprising the above-described polynucleotides or vectors are provided. Described are also methods for identifying and obtaining inhibitors for therapy of disorders related to the malfunction of the CYP3A4 and CYP3A7 genes as well as methods of diagnosing the status of such disorders. Pharmaceutical and diagnostic compositions comprising the above-described polynucleotides, vectors, proteins, antibodies and inhibitors by the above-described method are provided. Said compositions are particularly useful for diagnosing and treating various diseases with drugs that are substrates, inhibitors or modulators of the CYP3A4 or CYP3A7 gene product.

    Abstract translation: 描述了诊断和治疗表型谱的一般手段和方法以及与CYP3A4和CYP3A7基因的几种形式的遗传异常表达和/或功能的重叠临床特征。 具体而言，提供了例如与药物代谢和/或敏感性不足相关的分子变异体CYP3A4和CYP3A7基因的多核苷酸，以及包含此类多核苷酸的载体。 此外，描述了包含此类多核苷酸或载体的宿主细胞及其用于生产变体CYP3A4和CYP3A7蛋白的用途。 另外，提供了变体CYP3A4和CYP3A7蛋白质和特异性识别这些蛋白质的抗体以及包含上述多核苷酸或载体的转基因非人动物。 还描述了用于鉴定和获得用于治疗与CYP3A4和CYP3A7基因功能障碍相关的病症的抑制剂的方法以及诊断这些病症状态的方法。 通过上述方法提供了包含上述多核苷酸，载体，蛋白质，抗体和抑制剂的药物和诊断组合物。 所述组合物特别适用于用作为CYP3A4或CYP3A7基因产物的底物，抑制剂或调节剂的药物来诊断和治疗各种疾病。

    POLYMORPHISMS IN THE HUMAN hPXR GENE AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS
    14.
    发明申请
    POLYMORPHISMS IN THE HUMAN hPXR GENE AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS 审中-公开
    人类hPXR基因多态性及其在诊断和治疗应用中的应用

    公开(公告)号：WO0120026A2

    公开(公告)日：2001-03-22

    申请号：PCT/EP0008827

    申请日：2000-09-08

    Applicant: EPIDAUROS BIOTECHNOLOGIE AG ,  WOJNOWSKI LESZEK ,  HUSTERT ELISABETH

    Inventor： WOJNOWSKI LESZEK ,  HUSTERT ELISABETH

    IPC: A01K67/027 ,  A61K31/7088 ,  A61K35/56 ,  A61K35/76 ,  A61K38/00 ,  A61K38/17 ,  A61K39/395 ,  A61K45/00 ,  A61K48/00 ,  A61P35/00 ,  A61P43/00 ,  C07K14/705 ,  C07K16/18 ,  C07K16/28 ,  C07K16/40 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N9/02 ,  C12N15/09 ,  C12N15/53 ,  C12P19/34 ,  C12P21/02 ,  C12Q1/68 ,  G01N33/15 ,  G01N33/50 ,  G01N33/53 ,  G01N33/566 ,  G01N33/574

    CPC classification number: C07K14/70567 ,  A01K2217/05 ,  C12N9/0077 ,  C12Q1/6883 ,  C12Q2600/156 ,  C12Q2600/158

    Abstract: Described are general means and methods of diagnosing and treating the phenotypic spectrum as well as the overlapping clinical characteristics with several forms of inherited abnormal expression and/or function of the hPXR gene. In particular, polynucleotides of molecular variant hPXR gene which, for example, are associated with insufficient metabolization and/or sensitivity of drugs, and vectors comprising such polynucleotides are provided. Furthermore, host cells comprising such polynucleotides or vectors and their use for the production of variant hPXR proteins are described. In addition, variant hPXR proteins and antibodies specifically recognizing such proteins as well as transgenic non-human animals comprising the above-described polynucleotide or vectors are provided. Described are also methods for identifying and obtaining inhibitors for therapy of disorders related to the malfunction of the hPXR gene as well as methods of diagnosing the status of such disorders. Pharmaceutical and diagnostic compositions comprising the above-described polynucleotides, vectors, proteins, antibodies and inhibitors by the above-described method are provided. Said compositions are particularly useful for diagnosing and treating various diseases with drugs that are substrates, inhibitors or modulators of the hPXR gene product.

    Abstract translation: 描述了诊断和治疗表型谱的一般手段和方法以及与几种形式的hPXR基因的遗传异常表达和/或功能的重叠临床特征。 特别地，提供了例如与药物的代谢不足和/或敏感性相关的分子变体hPXR基因的多核苷酸以及包含这种多核苷酸的载体。 此外，描述了包含这种多核苷酸或载体的宿主细胞及其用于产生变体hPXR蛋白的用途。 此外，提供变体hPXR蛋白质和特异性识别这些蛋白质的抗体以及包含上述多核苷酸或载体的转基因非人动物。 还描述了用于鉴定和获得用于治疗与hPXR基因的功能紊乱有关的障碍的抑制剂的方法以及诊断这些病症状态的方法。 提供了包含上述多核苷酸，载体，蛋白质，抗体和通过上述方法的抑制剂的药物和诊断组合物。 所述组合物特别可用于用作为hPXR基因产物的底物，抑制剂或调节剂的药物诊断和治疗各种疾病。

    "> MEANS AND METHODS FOR IMPROVED TREATMENT USING
    15.
    发明申请
    MEANS AND METHODS FOR IMPROVED TREATMENT USING "SETRONES" 审中-公开
    使用“SETRONES”进行改进治疗的手段和方法

    公开(公告)号：WO2003100091A1

    公开(公告)日：2003-12-04

    申请号：PCT/EP2003/005366

    申请日：2003-05-22

    Applicant: EPIDAUROS BIOTECHNOLOGIE AG ,  BROCKMÖLLER, Hans, Jürgen

    Inventor： BROCKMÖLLER, Hans, Jürgen

    IPC: C12Q1/68

    CPC classification number: A61K31/404 ,  A61K31/4178 ,  A61K31/46 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/172

    Abstract: The present invention relates to the use of "setrones" for the preparation of a pharmaceutical composition for treating and/or preventing "setrone-treatable diseases" in a patient having a genotype with a first or second variant allele which comprises a polynucleotide in accordance with the present invention. Preferably, a nucleotide deletion, addition and/or substitution comprised by said polynucleotide results in an altered expression of the first and/or second variant allele compared to the corresponding wild type allele or an altered activity of the polypeptide encoded by the variant allele compared to the polypeptide encoded by the corresponding wild type allele. Finally, the present invention relates to a method for selecting a suitable therapy for a subject suffering from "setrone-treatable diseases as well as to methods of treatment for treating and/or preventing "setrone-treatable diseases" .

    Abstract translation: 本发明涉及用于制备用于治疗和/或预防具有第一或第二变异等位基因的基因型的患者中的“可固定化可治疗疾病”的药物组合物的用途，所述第一或第二变异等位基因包含根据 本发明。 优选地，由所述多核苷酸组成的核苷酸缺失，添加和/或取代导致与相应的野生型等位基因相比，第一和/或第二变异等位基因的表达改变，或由变异等位基因编码的多肽的改变的活性与 由相应的野生型等位基因编码的多肽。 最后，本发明涉及一种选择适合于患有“可治疗的顽固性疾病”的受试者以及用于治疗和/或预防“可安定可治疗的疾病”的治疗方法的方法。

    IRINOTECAN FOR TREATMENT OF CANCER
    17.
    发明申请
    IRINOTECAN FOR TREATMENT OF CANCER 审中-公开

    公开(公告)号：WO2003013537A3

    公开(公告)日：2003-02-20

    申请号：PCT/EP2002/008218

    申请日：2002-07-23

    Applicant: EPIDAUROS BIOTECHNOLOGIE AG ,  HEINRICH, Günther ,  KERB, Reinhold

    Inventor： HEINRICH, Günther ,  KERB, Reinhold

    IPC: A61K31/4745

    Abstract: The present invention relates to the use of irinotecan or a derivative thereof for the preparation of a pharmaceutical composition for treating colorectal cancer, cervical cancer, gastric cancer, lung cancer, malignant glioma, ovarian cancer, and pancreatic cancer in a patient having a genotype with a first, a second, a third, and/or a fourth variant allele which comprises a polynucleotide in accordance with the present invention. Preferably, a nucleotide deletion, addition and/or substitution comprised by said polynucleotide results in an altered expression of a first, a second, a third and/or a fourth variant allele compared to the corresponding wild type allele or an altered activity of the polypeptide encoded by the variant allele compared to the polypeptide encoded by the corresponding wild type allele. Finally, the present invention relates to a method for selecting a suitable therapy for a subject suffering from colorectal cancer, cervical cancer, gastric cancer, lung cancer, malignant glioma, ovarian cancer, and pancreatic cancer.

    METHODS FOR THE TREATMENT OF CANCER WITH IRINOTECAN BASED ON CYP3A5
    19.
    发明申请
    METHODS FOR THE TREATMENT OF CANCER WITH IRINOTECAN BASED ON CYP3A5 审中-公开

    公开(公告)号：WO2003013534A3

    公开(公告)日：2003-02-20

    申请号：PCT/EP2002/008219

    申请日：2002-07-23

    Applicant: EPIDAUROS BIOTECHNOLOGIE AG ,  HEINRICH, Günther ,  KERB, Reinhold

    Inventor： HEINRICH, Günther ,  KERB, Reinhold

    IPC: A61K31/4745

    Abstract: The present invention relates to the use of irinotecan or a derivative thereof for the preparation of a pharmaceutical composition for treating cancer, especially, colorectal cancer, cervical cancer, gastric cancer, lung cancer, malignant glioma, ovarian cancer, and pancreatic cancer in a patient having a genotype with a variant allele which comprises a polynucleotide in accordance with the present invention. Preferably, a nucleotide deletion, addition and/or substitution comprised by said polynucleotide results in an altered expression of variant allele compared to the corresponding wild type allele or an altered activity of the polypeptide encoded by the variant allele compared to the polypeptide encoded by the corresponding wild type allele. Finally, the present invention relates to a method for selecting a suitable therapy for a subject suffering from cancer, especially, colorectal cancer, cervical cancer, gastric cancer, lung cancer, malignant glioma, ovarian cancer, and pancreatic cancer.

    IRINOTECAN FOR TREATMENT OF CANCER
    20.
    发明申请
    IRINOTECAN FOR TREATMENT OF CANCER 审中-公开
    IRINOTECAN治疗癌症

    公开(公告)号：WO03013537A9

    公开(公告)日：2004-04-29

    申请号：PCT/EP0208218

    申请日：2002-07-23

    Applicant: EPIDAUROS BIOTECHNOLOGIE AG ,  HEINRICH GUENTHER ,  KERB REINHOLD

    Inventor： HEINRICH GUENTHER ,  KERB REINHOLD

    IPC: C12N15/09 ,  A61K31/235 ,  A61K31/277 ,  A61K31/341 ,  A61K31/343 ,  A61K31/352 ,  A61K31/353 ,  A61K31/409 ,  A61K31/4152 ,  A61K31/4709 ,  A61K31/4741 ,  A61K31/4745 ,  A61K31/49 ,  A61K31/496 ,  A61K31/519 ,  A61K31/565 ,  A61K31/566 ,  A61K31/575 ,  A61K38/00 ,  A61K45/00 ,  A61P1/00 ,  A61P1/18 ,  A61P11/00 ,  A61P15/00 ,  A61P25/00 ,  A61P35/00 ,  A61P43/00 ,  C07D491/052 ,  C07D491/22 ,  C12Q1/68

    CPC classification number: A61K31/4741 ,  A61K31/4745

    Abstract: The present invention relates to the use of irinotecan or a derivative thereof for the preparation of a pharmaceutical composition for treating colorectal cancer, cervical cancer, gastric cancer, lung cancer, malignant glioma, ovarian cancer, and pancreatic cancer in a patient having a genotype with a first, a second, a third, and/or a fourth variant allele which comprises a polynucleotide in accordance with the present invention. Preferably, a nucleotide deletion, addition and/or substitution comprised by said polynucleotide results in an altered expression of a first, a second, a third and/or a fourth variant allele compared to the corresponding wild type allele or an altered activity of the polypeptide encoded by the variant allele compared to the polypeptide encoded by the corresponding wild type allele. Finally, the present invention relates to a method for selecting a suitable therapy for a subject suffering from colorectal cancer, cervical cancer, gastric cancer, lung cancer, malignant glioma, ovarian cancer, and pancreatic cancer.

    Abstract translation: 本发明涉及伊立替康或其衍生物在具有基因型的患者中制备用于治疗结肠直肠癌，宫颈癌，胃癌，肺癌，恶性胶质瘤，卵巢癌和胰腺癌的药物组合物的用途， 第一，第二，第三和/或第四变体等位基因，其包含根据本发明的多核苷酸。 优选地，与相应的野生型等位基因相比，所述多核苷酸所包含的核苷酸缺失，添加和/或取代导致第一，第二，第三和/或第四变体等位基因的改变的表达或多肽的改变的活性 由相应野生型等位基因编码的多肽与变体等位基因编码。 最后，本发明涉及用于选择患有结肠直肠癌，宫颈癌，胃癌，肺癌，恶性胶质瘤，卵巢癌和胰腺癌的受试者的合适疗法的方法。

Patent Agency Ranking